Print Page  Close Window

SEC Filings

10-K
MYOKARDIA INC filed this Form 10-K on 03/08/2018
Entire Document
 

 

PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

None.

 

 

 

(a) Total Number of

Shares Purchased (1)

 

 

(b) Average Price

Paid per Share

 

 

(c) Total Number of

Shares Purchased

as Part of Publicly Announced

Plans or Programs

 

 

(d) Maximum Number

(or Approximate Dollar

Value) of Shares

that May Yet Be

Purchased Under the

Plans or Programs

 

Period

 

(in thousands, except per share amounts)

 

October 1, 2017 through October 31, 2017

 

 

 

 

$

 

 

 

 

 

 

 

November 1, 2017 through November 30, 2017

 

 

1,559

 

 

 

1.51

 

 

 

 

 

 

 

December 1, 2017 through December 31, 2017

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

1,559

 

 

$

1.51

 

 

 

 

 

 

 

 

 

(1)

Under certain stock purchase agreements with employees, we have the right to repurchase common stock at the lower of fair value and the stockholders' original purchase price, which right lapses according to individual vesting schedules. Reflects shares of common stock repurchased in connection with the termination of services by certain employees.

ITEM 6.

SELECTED CONSOLIDATED FINANCIAL DATA

You should read the selected historical financial data below in conjunction with the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. The selected financial data set forth below is derived from our audited consolidated financial statements and may not be indicative of future operating results.

 

 

 

Year Ended December 31,

 

(In thousands, except share and per share data)

 

2017

 

 

2016

 

 

2015

 

 

2014

 

 

2013

 

Consolidated Statement of Operations Data:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Collaboration and license revenue

 

$

22,500

 

 

$

39,199

 

 

$

14,199

 

 

$

5,916

 

 

$

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

48,136

 

 

 

36,215

 

 

 

28,393

 

 

 

18,296

 

 

 

11,603

 

General and administrative

 

 

21,973

 

 

 

16,289

 

 

 

9,019

 

 

 

4,838

 

 

 

2,029

 

Total operating expenses

 

 

70,109

 

 

 

52,504

 

 

 

37,412

 

 

 

23,134

 

 

 

13,632

 

Loss from operations

 

 

(47,609

)

 

 

(13,305

)

 

 

(23,213

)

 

 

(17,218

)

 

 

(13,632

)

Interest and other income (loss), net

 

 

1,657

 

 

 

153

 

 

 

(47

)

 

 

2

 

 

 

 

Change in fair value of redeemable convertible

   preferred stock call option liability

 

 

 

 

 

 

 

 

314

 

 

 

387

 

 

 

932

 

Net loss

 

 

(45,952

)

 

 

(13,152

)

 

 

(22,946

)

 

 

(16,829

)

 

 

(12,700

)

Cumulative dividend relating to redeemable

   convertible preferred stock

 

 

 

 

 

 

 

 

(5,151

)

 

 

(2,864

)

 

 

(1,087

)

Accretion of redeemable convertible preferred

   stock to redemption value

 

 

 

 

 

 

 

 

(98

)

 

 

(158

)

 

 

(179

)

Net loss attributable to common stockholders

 

$

(45,952

)

 

$

(13,152

)

 

$

(28,195

)

 

$

(19,851

)

 

$

(13,966

)

Net loss per share attributable to common

   stockholders, basic and diluted

 

$

(1.40

)

 

$

(0.48

)

 

$

(4.48

)

 

$

(11.30

)

 

$

(11.98

)

Shares used to compute net loss per share attributable

   to common stockholders, basic and diluted

 

 

32,832,514

 

 

 

27,475,792

 

 

 

6,292,800

 

 

 

1,756,900

 

 

 

1,165,867

 

 

 

 

 

As of December 31,

 

 

 

2017

 

 

2016

 

 

2015

 

 

2014

 

 

2013

 

Consolidated Balance Sheet Data:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

224,571

 

 

$

135,797

 

 

$

112,265

 

 

$

43,648

 

 

$

1,911

 

Working capital

 

 

218,521

 

 

 

153,275

 

 

 

91,572

 

 

 

26,348

 

 

 

(125

)

Total assets

 

 

282,808

 

 

 

201,306

 

 

 

116,580

 

 

 

46,889

 

 

 

4,703

 

Accumulated deficit

 

 

(123,797

)

 

 

(77,837

)

 

 

(64,685

)

 

 

(36,906

)

 

 

(17,247

)

Total stockholders’ equity (deficit)

 

$

241,734

 

 

$

145,382

 

 

$

93,873

 

 

$

(36,906

)

 

$

(17,247

)

 

62